Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cytomx Thera (CTMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 791,726
  • Shares Outstanding, K 45,007
  • Annual Sales, $ 71,620 K
  • Annual Income, $ -43,100 K
  • 36-Month Beta 0.91
  • Price/Sales 9.37
  • Price/Cash Flow N/A
  • Price/Book 5.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.49
  • Number of Estimates 7
  • High Estimate -0.38
  • Low Estimate -0.60
  • Prior Year 0.02
  • Growth Rate Est. (year over year) -2,550.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.36 +16.21%
on 01/29/19
19.75 -9.62%
on 02/05/19
+1.74 (+10.80%)
since 01/22/19
3-Month
12.88 +38.59%
on 11/23/18
19.75 -9.62%
on 02/05/19
+4.94 (+38.26%)
since 11/21/18
52-Week
12.51 +42.69%
on 11/20/18
35.00 -49.00%
on 03/08/18
-10.75 (-37.59%)
since 02/22/18

Most Recent Stories

More News
Analysis: Positioning to Benefit within Jacobs Engineering Group, Ares Capital, CytomX Therapeutics, FuelCell Energy, Timken, and Farmland Partners -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Jacobs Engineering Group Inc....

CTMX : 17.89 (+1.71%)
FCEL : 0.58 (unch)
JEC : 74.36 (+0.81%)
TKR : 43.64 (+0.55%)
FPI : 5.30 (-2.93%)
ARCC : 17.47 (+0.75%)
CytomX Therapeutics to Announce Full-Year 2018 Financial Results and Host Webcast Conference Call

-Teleconference Scheduled for February 27, 2019, at 5:00 p.m. ET-

CTMX : 17.89 (+1.71%)
Shares of CTMX Up 25.0% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Cytomx Therapeut (NASDAQ:CTMX) on January 4th, 2019 at $15.32. In approximately 1 month, Cytomx Therapeut has returned 25.00% as of today's recent price of $19.15.

CTMX : 17.89 (+1.71%)
CytomX Therapeutics Announces Senior Management Appointments

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 17.89 (+1.71%)
Cytomx Therapeut Has Returned 23.2% Since SmarTrend Recommendation (CTMX)

SmarTrend identified an Uptrend for Cytomx Therapeut (NASDAQ:CTMX) on January 4th, 2019 at $15.32. In approximately 1 month, Cytomx Therapeut has returned 23.17% as of today's recent price of $18.87.

CTMX : 17.89 (+1.71%)
CytomX Therapeutics to Host Research and Development Day on February 26, 2019

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 17.89 (+1.71%)
CytomX Therapeutics Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in CytomX Therapeutics.

CTMX : 17.89 (+1.71%)
CytomX Therapeutics Announces Technology Acquisition From Agensys, Inc., an Affiliate of Astellas Pharma Inc.

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 17.89 (+1.71%)
ALPMF : 15.0000 (-0.20%)
Cytomx Therapeut Shares Down 33.1% Since SmarTrend's Sell Call (CTMX)

SmarTrend identified a Downtrend for Cytomx Therapeut (NASDAQ:CTMX) on August 15th, 2018 at $22.40. In approximately 5 months, Cytomx Therapeut has returned 33.07% as of today's recent price of $14.99....

CTMX : 17.89 (+1.71%)
Cytomx Therapeut Shares Down 39.2% Since SmarTrend's Sell Call (CTMX)

SmarTrend identified a Downtrend for Cytomx Therapeut (NASDAQ:CTMX) on August 15th, 2018 at $22.40. In approximately 4 months, Cytomx Therapeut has returned 39.18% as of today's recent price of $13.62....

CTMX : 17.89 (+1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade CTMX with:

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 18.18
1st Resistance Point 17.89
Last Price 17.89
1st Support Level 17.22
2nd Support Level 16.84

See More

52-Week High 35.00
Fibonacci 61.8% 26.41
Fibonacci 50% 23.76
Fibonacci 38.2% 21.10
Last Price 17.89
52-Week Low 12.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar